King Luther Capital Management Corp Has $10.15 Million Stake in scPharmaceuticals Inc. (NASDAQ:SCPH)

King Luther Capital Management Corp boosted its position in scPharmaceuticals Inc. (NASDAQ:SCPH) by 0.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,225,790 shares of the company’s stock after buying an additional 20,650 shares during the period. King Luther Capital Management Corp owned approximately 4.45% of scPharmaceuticals worth $10,150,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. AIGH Capital Management LLC increased its position in shares of scPharmaceuticals by 3.4% during the second quarter. AIGH Capital Management LLC now owns 3,504,365 shares of the company’s stock valued at $15,244,000 after acquiring an additional 115,206 shares during the last quarter. Thrivent Financial for Lutherans boosted its holdings in shares of scPharmaceuticals by 1.4% in the third quarter. Thrivent Financial for Lutherans now owns 1,048,938 shares of the company’s stock worth $4,783,000 after acquiring an additional 14,866 shares during the period. Rice Hall James & Associates LLC boosted its stake in scPharmaceuticals by 25.0% in the 3rd quarter. Rice Hall James & Associates LLC now owns 621,665 shares of the company’s stock worth $2,835,000 after purchasing an additional 124,438 shares during the period. Bank of Montreal Can purchased a new position in scPharmaceuticals during the second quarter valued at approximately $1,544,000. Finally, Bank of New York Mellon Corp grew its position in shares of scPharmaceuticals by 15.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 86,101 shares of the company’s stock valued at $375,000 after purchasing an additional 11,269 shares in the last quarter. 89.52% of the stock is owned by institutional investors and hedge funds.

scPharmaceuticals Trading Up 3.0 %

NASDAQ:SCPH opened at $3.46 on Friday. scPharmaceuticals Inc. has a one year low of $3.08 and a one year high of $6.71. The company’s 50-day simple moving average is $4.36 and its 200 day simple moving average is $4.46. The firm has a market capitalization of $173.14 million, a P/E ratio of -1.82 and a beta of 0.15. The company has a debt-to-equity ratio of 1.66, a current ratio of 8.08 and a quick ratio of 6.89.

Analyst Ratings Changes

SCPH has been the topic of several research analyst reports. Craig Hallum decreased their price objective on shares of scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of scPharmaceuticals in a research note on Thursday, November 14th.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.